Researchers conducted a head-to-head test of the second-generation vaccine CV2CoV compared with CVnCoV. The scientists assessed the vaccines' ability to provoke an immune response as well as their protective efficacy against COVID-19 in non-human primates.
from Top Health News -- ScienceDaily https://ift.tt/3xcjW80
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
While sales to original equipment manufacturers declined 16.3% year on year in FY20, the replacement market sales declined by a modest 2.6% ...
-
India's passenger vehicle sales are expected to grow between 3-5 percent in the current fiscal year, after expanding at the slowest pace...
-
The earnings momentum has been quite resilient and the policy momentum quite focused towards improving the infrastructure and attractiveness...
No comments:
Post a Comment